Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Catalyst Pharmaceuticals, Inc. or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Catalyst Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Catalyst Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Latest Biotechnology and Catalyst Pharmaceuticals, Inc., Aurinia Pharmaceuticals Inc. Stock News
As of November 18, 2025, Catalyst Pharmaceuticals, Inc. had a $2.8 billion market capitalization, compared to the Biotechnology median of $210.4 million. Catalyst Pharmaceuticals, Inc.’s stock is NA in 2025, NA in the previous five trading days and up 4.61% in the past year.
Currently, Catalyst Pharmaceuticals, Inc.’s price-earnings ratio is 13.3. Catalyst Pharmaceuticals, Inc.’s trailing 12-month revenue is $578.2 million with a 37.6% net profit margin. Year-over-year quarterly sales growth most recently was 15.3%. Analysts expect adjusted earnings to reach $2.504 per share for the current fiscal year. Catalyst Pharmaceuticals, Inc. does not currently pay a dividend.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 28.2. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
How We Compare Catalyst Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Catalyst Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions